The modern miracle of a cure for a disease is frequently just the best medication that can be developed to control it.
Beta interferon reduces the frequency and severity of acute attacks.
We would like to improve upon these results for all MS patients. Robert Knobler, MD, co-director of Jefferson's MS Center, has been pursuing the causes and mechanisms for control of MS throughout his career. He is primary investigator of the 2CDA study. Tizanidine is another drug that is being evaluated for its ability to control spasticity. The Multiple Sclerosis Center at Jefferson manages approximately 1,600 patients, with about 300 of those enrolled in some type of clinical trial.